Want to see IPHA full AI Analyst Report?
IPHA Stock Chart & Stats
$2.27
$0.02(1.14%)
At close: 4:00 PM EDT
$2.27
$0.02(1.14%)
Day’s Range― - ―
52-Week Range$1.17 - $2.71
Previous Close$1.74
Volume2.54K
Average Volume (3M)49.74K
Market Cap
$169.37M
Enterprise Value$183.29M
Total Cash (Recent Filing)$10.89M
Total Debt (Recent Filing)$20.20M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Mar 25, 2027EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding111,718,925
10 Day Avg. Volume28,597
30 Day Avg. Volume49,743
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)-6.14
Price to Sales (P/S)47.79
P/FCF Ratio-3.81
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue169.09
Enterprise Value/Gross Profit9.94
Enterprise Value/Ebitda-3.53
Forecast
1Y Price Target
$6.67Price Target Upside193.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$56.82M
Bulls Say, Bears Say
Bulls Say
Partnered Pipeline And Regulatory ProgressThe Sobi partnership and initiation of a confirmatory Phase 3 study provide external validation and a clearer development path for lacutamab. FDA breakthrough and fast track designations may support regulatory interaction and improve the program’s ability to advance toward potential commercialization.
Extended Funding RunwayFunding that extends the projected runway through early 2028 gives Innate time to execute clinical programs without immediately requiring another financing. This supports continuity across development activities and preserves the opportunity to reach meaningful data milestones before capital needs become urgent.
Broadening Antibody-drug Conjugate PlatformA portfolio built around multiple differentiated ADC design strategies can create several opportunities beyond a single clinical asset. This broadens potential pipeline value, supports reuse of internal development capabilities, and may improve the company’s long-term partnering prospects if candidates show clinical differentiation.
Bears Say
Persistent Operating Losses And Cash BurnPersistent negative operating and free cash flow shows that Innate is not currently self-funding its research and development activities. Continued cash consumption increases reliance on partner payments, grants, or new capital and can constrain the pace and breadth of future clinical investment.
Negative Shareholders’ EquityNegative shareholders’ equity reflects the cumulative impact of recent losses on the capital base and leaves less balance-sheet flexibility. Although debt declined, the weakened capitalization may increase dependence on external financing and make future fundraising more dilutive or financially restrictive.
Early Clinical Evidence And Expansion Funding NeedsThe next-generation ADC opportunity remains dependent on early clinical observations being confirmed in larger and more informative datasets. In addition, broader tumor-type expansion requires additional funding, creating execution and capital-allocation constraints before the platform’s full potential can be tested.
Innate Pharma News
IPHA FAQ
What was Innate Pharma’s price range in the past 12 months?
Innate Pharma lowest stock price was $1.17 and its highest was $2.71 in the past 12 months.
What is Innate Pharma’s market cap?
Innate Pharma’s market cap is $169.37M.
When is Innate Pharma’s upcoming earnings report date?
Innate Pharma’s upcoming earnings report date is Mar 25, 2027 which is in 153 days.
How were Innate Pharma’s earnings last quarter?
Innate Pharma released its earnings results on Sep 17, 2026. The company reported -$0.241 earnings per share for the quarter, missing the consensus estimate of -$0.185 by -$0.056.
Is Innate Pharma overvalued?
According to Wall Street analysts Innate Pharma’s price is currently Undervalued.
Does Innate Pharma pay dividends?
Innate Pharma does not currently pay dividends.
What is Innate Pharma’s EPS estimate?
Innate Pharma’s EPS estimate is -0.29.
How many shares outstanding does Innate Pharma have?
Innate Pharma has 111,718,925 shares outstanding.
What happened to Innate Pharma’s price movement after its last earnings report?
Innate Pharma reported an EPS of -$0.241 in its last earnings report, missing expectations of -$0.185. Following the earnings report the stock price went down -4.975%.
Which hedge fund is a major shareholder of Innate Pharma?
Currently, no hedge funds are holding shares in IPHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innate Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (193.69% Upside)
$6.67 (193.69% Upside)
Blogger Sentiment
Bullish
IPHA Sentiment 67%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.23%
12-Months-Change
Fundamentals
Return on Equity
152.56%
Trailing 12-Months
Asset Growth
-63.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Innate Pharma
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
IPHA Company Deck
IPHA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive outlook, with the lacutamab partnership closing, Phase 3 initiation, preliminary IPH4.5 thousand objective responses and favorable safety observations, completed monalizumab enrollment, multiple upcoming catalysts, and a cash runway expected through the end of the first quarter of 2028. The main qualifications were that IPH4.5 thousand data remain early, the post-enfortumab vedotin urothelial cancer setting lacks an established second-line standard, and broader development could require additional funding.View all IPHA earnings summariesIPHA Stock 12 Month Forecast
Average Price Target
$6.67
▲(193.69% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.09% Other Institutional Investors
99.91% Public Companies and
Individual Investors